Paroxysmal nocturnal hemoglobinuria (PNH) is an uncommon condition in which a person’s own immune system activity (specifically the complement system) can damage blood cells. The effects can be serious—such as anemia, fatigue, and increased risk of blood clots—yet early symptoms may be nonspecific. Today, diagnosis is usually confirmatory with specialized blood testing, and treatment often focuses on reducing hemolysis (red cell breakdown), preventing complications, and managing bone marrow failure when present.

Hemoglobinuria: what it means in PNH

Hemoglobinuria refers to hemoglobin appearing in the urine. In PNH, red blood cells can break apart within the bloodstream (intravascular hemolysis), releasing hemoglobin. When the amount of free hemoglobin exceeds what the body can bind and recycle, the kidneys filter it, leading to dark or “tea-colored” urine. Despite the condition’s historical name, hemoglobinuria is not limited to nighttime; it may be most noticeable in the morning simply because urine is more concentrated after sleep.

Clinically, hemoglobinuria can be confused with blood in the urine from other causes (such as kidney stones or urinary tract disease). A key distinction is that urine dipstick tests may show “blood” due to hemoglobin, while microscopic examination reveals few or no intact red blood cells. Over time, repeated hemoglobin exposure may contribute to kidney stress, so clinicians often monitor kidney function along with markers of hemolysis.

Because hemoglobinuria is a sign rather than a diagnosis, it is usually interpreted alongside other findings in PNH: anemia (sometimes with elevated reticulocytes), elevated lactate dehydrogenase (LDH), low haptoglobin, and symptoms such as fatigue, shortness of breath, abdominal pain, difficulty swallowing, or erectile dysfunction (linked to nitric oxide depletion from free hemoglobin).

Hemoglobinuria causes and why PNH is different

Hemoglobinuria causes include several medical situations that lead to red blood cell destruction in the circulation. Examples include transfusion reactions, certain infections, mechanical hemolysis (for instance, from artificial heart valves), severe burns, and some inherited or acquired hemolytic anemias. What makes PNH distinct is its underlying mechanism: an acquired genetic change (mutation) in hematopoietic stem cells leads to blood cells lacking protective proteins on their surface, making them vulnerable to complement-mediated injury.

In practical terms, this means PNH may present in different “patterns,” and understanding those patterns helps guide care. Some people have predominantly hemolytic disease with marked intravascular hemolysis and hemoglobinuria. Others have significant bone marrow failure features, overlapping with aplastic anemia or myelodysplastic syndromes, which can cause low white blood cells and platelets in addition to anemia. A third group has mixed features.

A major complication clinicians watch for is thrombosis (blood clots), which can occur in typical veins (like in the legs or lungs) or in less common sites such as abdominal veins. The clot risk is one reason PNH is treated and monitored closely even when symptoms fluctuate. Management is individualized and may include complement inhibition (to reduce hemolysis and often lower clot risk), anticoagulation in selected situations, transfusion support, and folate or iron management depending on lab patterns.

Modern therapy has changed the outlook for many people with PNH. Complement inhibitors can reduce intravascular hemolysis and hemoglobinuria and may improve quality of life, though they do not “cure” the abnormal stem cell clone. Some patients still experience anemia from ongoing extravascular hemolysis or bone marrow failure. In specific cases—especially severe bone marrow failure—stem cell transplantation may be considered, but it carries significant risks and is reserved for carefully selected situations.

Paroxysmal nocturnal hemoglobinuria radiology: what imaging can show

Paroxysmal nocturnal hemoglobinuria radiology is not about finding a single signature image that diagnoses PNH; the definitive test is typically flow cytometry that identifies missing protective surface proteins on blood cells. Instead, imaging is used to evaluate complications, alternative diagnoses, and organ impact.

One of the most important roles for radiology is assessing suspected thrombosis. Depending on symptoms, clinicians may use ultrasound for limb clots, CT pulmonary angiography for pulmonary embolism, or CT/MR venography to evaluate abdominal or hepatic veins when pain, swelling, or liver-related symptoms occur. Because clotting can involve atypical locations in PNH, imaging choice is driven by clinical suspicion rather than a routine “PNH scan.”

Radiology may also support evaluation of kidney and abdominal issues. Chronic hemolysis can contribute to changes in kidney function, and imaging may be performed if there is concern for structural kidney disease, obstruction, or other causes of dark urine. In some hemolytic states, iron deposition can occur in organs; while MRI can detect iron overload patterns in certain contexts, interpretation is nuanced and depends on overall clinical and laboratory findings.

From a “today” perspective, the most helpful way to think about imaging in PNH is as targeted problem-solving: confirming or ruling out clots, assessing abdominal pain, and checking for complications that may alter treatment decisions.

This article is for informational purposes only and should not be considered medical advice. Please consult a qualified healthcare professional for personalized guidance and treatment.

Living with PNH often involves ongoing monitoring rather than a one-time intervention: tracking hemolysis markers, kidney function, blood counts, and symptoms that could indicate clotting or marrow failure. With better diagnostic tools and complement-directed therapies, many patients can achieve improved symptom control, while careful individualized planning remains essential because PNH varies widely in severity and associated risks.